However, combined osteopontin targeting in the early and late acute phase of ischemic stroke by administration of therapeutic antibody more efficiently improved BBB recovery both in the peri-infarct region and infarct core that is associated with more prominent edema reduction and less stroke tissue damage (Fig. 6). The gene discussed is SPP1; the disease is stroke disorder.